FogPharma Secures $145M in Series E Funding to Advance Intracellular Peptide Therapy for Solid Tumors

- **Lead Program**: FOG-001, a Helicon therapeutic designed to block the Wnt/β-catenin signaling pathway, is currently under evaluation in a Phase 1/2 clinical trial for solid tumors, especially colorectal cancer.
- **Wnt/β-catenin Signaling Pathway**: This pathway is a frequent contributor to cancer development, particularly in colorectal cancer, where mutations are common.
- **Expanded Development Strategy**: The funding allows FogPharma to expand clinical development and commercialization strategies for FOG-001 and enhances discovery efforts against additional intracellular targets related to various diseases.
- **Notable Investors**: New investors include Alexis Borisy (who joined FogPharma's board), RA Capital Management, Rock Springs Capital, General Catalyst, Marshall Wace, Samsara Biocapital, Foresite Capital, Catalio Capital Management, and Sixty Degree Capital.
- **Existing Investors**: Existing investors supporting the funding include ARCH Venture Partners, Fidelity, and GV.
- **Pipeline Expansion**: The funding supports the advancement of FogPharma's broader pipeline alongside the primary focus on FOG-001.